A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

May 2, 2019

Study Completion Date

May 2, 2019

Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL

Ligelizumab

QGE031 240 mg s.c. q4w

Trial Locations (67)

333

Novartis Investigative Site, Taoyuan District

407

Novartis Investigative Site, Taichung

2010

Novartis Investigative Site, Sydney

2560

Novartis Investigative Site, Campbelltown

3002

Novartis Investigative Site, East Melbourne

4102

Novartis Investigative Site, Woolloongabba

5000

Novartis Investigative Site, Adelaide

10002

Novartis Investigative Site, Taipei

12462

Novartis Investigative Site, Athens

13353

Novartis Investigative Site, Berlin

14004

Novartis Investigative Site, Córdoba

20602

Novartis Investigative Site, Waldorf

28040

Novartis Investigative Site, Madrid

28041

Novartis Investigative Site, Madrid

28801

Novartis Investigative Site, Asheville

28922

Novartis Investigative Site, Alcorcón

29009

Novartis Investigative Site, Málaga

30625

Novartis Investigative Site, Hanover

34233

Novartis Investigative Site, Sarasota

35209

Novartis Investigative Site, Birmingham

41009

Novartis Investigative Site, Seville

42301

Novartis Investigative Site, Owensboro

43617

Novartis Investigative Site, Toledo

45231

Novartis Investigative Site, Cincinnati

46015

Novartis Investigative Site, Valencia

47713

Novartis Investigative Site, Evansville

48149

Novartis Investigative Site, Münster

55131

Novartis Investigative Site, Mainz

55905

Novartis Investigative Site, Rochester

63141

Novartis Investigative Site, St Louis

72205

Novartis Investigative Site, Little Rock

75230

Novartis Investigative Site, Dallas

76132

Novartis Investigative Site, Fort Worth

79106

Novartis Investigative Site, Freiburg im Breisgau

80377

Novartis Investigative Site, Munich

85251

Novartis Investigative Site, Scottsdale

97035

Novartis Investigative Site, Lake Oswego

115478

Novartis Investigative Site, Moscow

194223

Novartis Investigative Site, Saint Petersburg

195112

Novartis Investigative Site, Saint Petersburg

214019

Novartis Investigative Site, Smolensk

454092

Novartis Investigative Site, Chelyabinsk

02906

Novartis Investigative Site, Providence

05403

Novartis Investigative Site, South Burlington

M4V 1R2

Novartis Investigative Site, Toronto

N2J 1C4

Novartis Investigative Site, Waterloo

G1V 4W2

Novartis Investigative Site, Québec

01307

Novartis Investigative Site, Dresden

115 27

Novartis Investigative Site, Athens

Novartis Investigative Site, Athens

080 0013

Novartis Investigative Site, Obihiro

650-0017

Novartis Investigative Site, Kobe

221-0825

Novartis Investigative Site, Yokohama

861-3101

Novartis Investigative Site, Kamimashi-gun

602-8566

Novartis Investigative Site, Kyoto

593-8324

Novartis Investigative Site, Sakai

330-0854

Novartis Investigative Site, Saitama

194-0013

Novartis Investigative Site, Machida

143-0023

Novartis Investigative Site, Ōta-ku

141 8625

Novartis Investigative Site, Shinagawa Ku

734-8551

Novartis Investigative Site, Hiroshima

08003

Novartis Investigative Site, Barcelona

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

03010

Novartis Investigative Site, Alicante

08041

Novartis Investigative Site, Barcelona

BA21 4AT

Novartis Investigative Site, Yeovil

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY